FDA label
What is Actemra used for?
Actemra contains tocilizumab. The FDA-approved uses below are quoted from the Indications and Usage section of its DailyMed label.
Source: DailyMed SPL label file dated 2026-10-23. Publisher page
The FDA label for Actemra lists 7 uses: Rheumatoid Arthritis (RA); Giant Cell Arteritis (GCA); Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD); Polyarticular Juvenile Idiopathic Arthritis (PJIA); and 3 more.
Run it in Rivvi
Which 2027 plans near you dropped or restricted Actemra?
Tier changes and new prior auth, step therapy or quantity limits, plan by plan.
Free to start. Opens Rivvi, the AI workspace for healthcare teams.
Actemra, injection, solution, concentrate
Indications and Usage, quoted from the label by Genentech, Inc. (BLA125276). Cross-references to other label sections are left out.
Rheumatoid Arthritis (RA)
ACTEMRA® (tocilizumab) is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs).
Giant Cell Arteritis (GCA)
ACTEMRA® (tocilizumab) is indicated for the treatment of giant cell arteritis (GCA) in adult patients.
Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
ACTEMRA® (tocilizumab) is indicated for slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease.
Polyarticular Juvenile Idiopathic Arthritis (PJIA)
ACTEMRA® (tocilizumab) is indicated for the treatment of active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older.
Systemic Juvenile Idiopathic Arthritis (SJIA)
ACTEMRA® (tocilizumab) is indicated for the treatment of active systemic juvenile idiopathic arthritis in patients 2 years of age and older.
Cytokine Release Syndrome (CRS)
ACTEMRA® (tocilizumab) is indicated for the treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome in adults and pediatric patients 2 years of age and older.
Coronavirus Disease 2019 (COVID-19)
ACTEMRA® (tocilizumab) is indicated for the treatment of coronavirus disease 2019 (COVID-19) in hospitalized adult and pediatric patients aged 2 years and older who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).
Source: DailyMed label, set id 2e5365ff-cb2a-4b16-b2c7-e35c6bf2de13, version 53, effective December 16, 2025. NDC 50242-135, one of 3 listings for this product.
Questions
What is Actemra used for?
The FDA label for Actemra lists 7 uses: Rheumatoid Arthritis (RA); Giant Cell Arteritis (GCA); Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD); Polyarticular Juvenile Idiopathic Arthritis (PJIA); and 3 more.
What drug class is Actemra?
FDA lists tocilizumab in the Interleukin-6 Receptor Antagonist established pharmacologic class.
Does this page cover off-label uses or dosing?
No. This page shows only the Indications and Usage section of the FDA label. Ask a pharmacist or prescriber about dosing.